cabergoline has been researched along with Liver Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bilbao, I; Egaña, N; García, C; Olaizola, I | 1 |
Borson-Chazot, F; Ilie, MD; Raverot, G; Raverot, V; Tronc, F; Vasiljevic, A | 1 |
2 other study(ies) available for cabergoline and Liver Neoplasms
Article | Year |
---|---|
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined Modality Therapy; Dacarbazine; Drug Substitution; Ergolines; Fatal Outcome; Headache; Humans; Hyperprolactinemia; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Proton Therapy; Temozolomide | 2017 |
Cabergoline in severe ectopic or occult Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adult; Aged; Cabergoline; Carcinoid Tumor; Cushing Syndrome; Dopamine Agonists; Female; Humans; Hydrocortisone; Ketoconazole; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Intraductal Neoplasms; Rectal Neoplasms; Steroid Synthesis Inhibitors; Thymus Neoplasms; Treatment Outcome | 2019 |